| scholarly article | Q13442814 |
| P50 | author | Wen Gao | Q88567525 |
| P2093 | author name string | Lin Zhou | |
| Liming Lu | |||
| Yun Wu | |||
| Dandan Zhao | |||
| Ruyong Yao | |||
| Yifeng Sun | |||
| Dongfang Tang | |||
| P2860 | cites work | PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma. | Q55003479 |
| ALK-Testing in non-small cell lung cancer (NSCLC): Immunohistochemistry (IHC) and/or fluorescence in-situ Hybridisation (FISH)?: Statement of the Germany Society for Pathology (DGP) and the Working Group Thoracic Oncology (AIO) of the German Cancer S | Q56964755 | ||
| Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types | Q87742270 | ||
| Cancer-associated oxidoreductase ERO1-α promotes immune escape through up-regulation of PD-L1 in human breast cancer | Q33648621 | ||
| Phosphorylation-regulated degradation of the tumor-suppressor form of PED by chaperone-mediated autophagy in lung cancer cells. | Q34400928 | ||
| The clinical relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 network in chemoresistant non-small-cell lung cancer | Q35399165 | ||
| miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint | Q36875531 | ||
| Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis. | Q36963025 | ||
| Reduced miR-3127-5p expression promotes NSCLC proliferation/invasion and contributes to dasatinib sensitivity via the c-Abl/Ras/ERK pathway | Q37734888 | ||
| Role of circulating-tumor DNA analysis in non-small cell lung cancer | Q38594780 | ||
| An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma | Q38749945 | ||
| Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy | Q39413872 | ||
| Sesamin induces autophagy in colon cancer cells by reducing tyrosine phosphorylation of EphA1 and EphB2. | Q39556548 | ||
| A population-based comparative effectiveness study of chemoradiation regimens and sequences in stage III non-small cell lung cancer | Q40155605 | ||
| Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study | Q40329884 | ||
| CLDN1 Increases Drug Resistance of Non-Small Cell Lung Cancer by Activating Autophagy via Up-Regulation of ULK1 Phosphorylation. | Q41076029 | ||
| mTORC1-independent autophagy regulates receptor tyrosine kinase phosphorylation in colorectal cancer cells via an mTORC2-mediated mechanism | Q42509388 | ||
| Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab | Q47783661 | ||
| Therapeutic implication of 'Iturin A' for targeting MD-2/TLR4 complex to overcome angiogenesis and invasion. | Q50769962 | ||
| The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer. | Q51474909 | ||
| P4510 | describes a project that uses | ImageJ | Q1659584 |
| P921 | main subject | lung cancer | Q47912 |
| P577 | publication date | 2018-05-04 | |
| P1433 | published in | Journal of Cellular and Molecular Medicine | Q1524063 |
| P1476 | title | The miR-3127-5p/p-STAT3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer |
| Q104459235 | A multivariable miRNA signature delineates the systemic hemodynamic impact of arteriovenous shunt placement in a pilot study |
| Q92454757 | Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC) |
| Q60044568 | Gene code CD274/PD-L1: from molecular basis toward cancer immunotherapy |
| Q92807802 | Knockdown of LncRNA SCAMP1 suppressed malignant biological behaviours of glioma cells via modulating miR-499a-5p/LMX1A/NLRC5 pathway |
| Q92080181 | Protective effect of hsa-miR-570-3p targeting CD274 on triple negative breast cancer by blocking PI3K/AKT/mTOR signaling pathway |
| Q93147363 | Recent Findings in the Regulation of Programmed Death Ligand 1 Expression |
| Q99630570 | Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives |
| Q60908274 | The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer |
| Q90718904 | The role of cancer-derived microRNAs in cancer immune escape |
| Q91965847 | [Role of STAT3 in Resistance of Non-small Cell Lung Cancer] |
Search more.